Teriparatide vs Matrixyl
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen and extracellular matrix production. It is one of the most well-studied anti-aging peptides with proven efficacy for wrinkle reduction.
Full details →Side-by-Side Comparison
| Aspect | Teriparatide | Matrixyl |
|---|---|---|
| Mechanism | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. | Mimics collagen breakdown fragments, triggering fibroblasts to produce new collagen, elastin, and other matrix components. Essentially tricks skin into repair mode without actual damage. |
| Typical Dosage | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. | Topical: 2-8% concentration in serums and creams. Matrixyl 3000 combines it with Palmitoyl Tetrapeptide-7 for enhanced effects. |
| Administration | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. | Topical application 1-2 times daily. Can be combined with other actives like retinol, vitamin C, and other peptides. |
| Side Effects | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. | Very well-tolerated. Rare mild irritation. Suitable for sensitive skin types. |
| Best For |